Prior to changing pulmonary hypertension medications from bosentan to macitentan, bosentan could have increased the hepatic metabolism of warfarin by inducing CYP2C9 and CYP3A4 activity and decreasing its anticoagulant effects. This evidence concerns the gene CYP2C9 and pulmonary arterial hypertension.